Gulletta Simone, Gasperetti Alessio, Schiavone Marco, Paglino Gabriele, Vergara Pasquale, Compagnucci Paolo, Bisceglia Caterina, Cireddu Manuela, Fierro Nicolai, D'Angelo Giuseppe, Sala Simone, Rampa Lorenzo, Casella Michela, Mazzone Patrizio, Dello Russo Antonio, Forleo Giovanni Battista, Della Bella Paolo
Department of Arrhythmology, San Raffaele Hospital, 20132 Milan, MI, Italy.
Cardiology Unit, Luigi Sacco University Hospital, 20157 Milan, MI, Italy.
J Clin Med. 2022 Nov 6;11(21):6583. doi: 10.3390/jcm11216583.
Background: Large-scale studies evaluating long-term recurrence rates in both idiopathic and non-idiopathic PVC catheter ablation (CA) patients have not been reported. Objective: To evaluate the efficacy and safety of idiopathic and non-idiopathic PVC CA, investigating the predictors of acute and long-term efficacy. Methods: This retrospective multicentric study included 439 patients who underwent PVC CA at three institutions from April-2015 to December-2021. Clinical success at 6 months’ follow-up, defined as a reduction of at least 80% of the pre-procedural PVC burden, was deemed the primary outcome. The secondary aims of the study were: clinical success at the last available follow-up, predictors of arrhythmic recurrences at long-term follow-up, and safety outcomes. Results: The median age was 51 years, with 24.9% patients being affected suffering from structural heart disease. The median pre-procedural PVC burden was 20.1%. PVCs originating from the RVOT were the most common index PVC observed (29.1%), followed by coronary cusp (CC) and non-outflow tract (OT) LV PVCs (23.1% and 19.0%). The primary outcome at 6 months was reached in 85.1% cases, with a significant reduction in the 24 h% PVC burden (−91.4% [−83.4; −96.7], p < 0.001); long-term efficacy was observed in 82.1% of cases at almost 3-year follow-up. The presence of underlying structural heart disease and non-OT LV region origin (aHR 1.77 [1.07−2.93], p = 0.027 and aHR = 1.96 [1.22−3.14], p = 0.005) was independently associated with recurrences. Conclusion: CA of both idiopathic and non-idiopathic PVCs showed a very good acute and long-term procedural success rate, with an overall low complication. Predictors of arrhythmic recurrence at follow-up were underlying structural heart disease and non-OT LV origin.
尚未有大规模研究评估特发性和非特发性室性早搏导管消融(CA)患者的长期复发率。目的:评估特发性和非特发性室性早搏CA的疗效和安全性,研究急性和长期疗效的预测因素。方法:这项回顾性多中心研究纳入了2015年4月至2021年12月在三家机构接受室性早搏CA的439例患者。6个月随访时的临床成功定义为术前室性早搏负荷至少降低80%,被视为主要结局。该研究的次要目标是:最后一次可用随访时的临床成功、长期随访时心律失常复发的预测因素以及安全性结局。结果:中位年龄为51岁,24.9%的患者患有结构性心脏病。术前室性早搏负荷的中位数为20.1%。起源于右心室流出道(RVOT)的室性早搏是最常见的索引室性早搏(29.1%),其次是冠状窦口(CC)和非流出道(OT)左心室室性早搏(23.1%和19.0%)。85.1%的病例在6个月时达到主要结局,24小时室性早搏负荷显著降低(-91.4%[-83.4;-96.7],p<0.001);在近3年的随访中,82.1%的病例观察到长期疗效。潜在结构性心脏病的存在和非OT左心室区域起源(调整后风险比1.77[1.07-2.93],p=0.027和调整后风险比=1.96[1.22-3.14],p=0.005)与复发独立相关。结论:特发性和非特发性室性早搏的CA均显示出非常好的急性和长期手术成功率,总体并发症较低。随访时心律失常复发的预测因素是潜在结构性心脏病和非OT左心室起源。